| # | Drug | Count |
|---|---|---|
| 0 | CYCLOPHOSPHAMIDE | 28 |
| 1 | CYCLOPHOSPHAMIDE FOR INJECTION | 28 |
| 2 | CYCLOPHOSPHAMIDE INJECTION, SOLUTION | 28 |
| 3 | CYTARABINE | 21 |
| 4 | TACROLIMUS | 20 |
| 5 | TACROLIMUS EXTENDED-RELEASE CAPSULES | 20 |
| 6 | TACROLIMUS OINTMENT 0.1% | 20 |
| 7 | RITUXIMAB | 18 |
| 8 | DOXORUBICIN | 17 |
| 9 | METHOTREXATE SODIUM | 17 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | IDARUBICIN HYDROCHLORIDE | 2 | 0.0017 |
| 1 | (DAUNORUBICIN AND CYTARABINE) LIPOSOME | 2 | 0.0008 |
| 2 | BUSULFAN | 12 | 0.0008 |
| 3 | EPCORITAMAB-BYSP | 1 | 0.0007 |
| 4 | VANCOMYCIN HYDROCHLORIDE | 6 | 0.0007 |
| 5 | AMIKACIN SULFATE | 1 | 0.0006 |
| 6 | AMPHOTERICIN B | 7 | 0.0005 |
| 7 | MINOCYCLINE | 6 | 0.0005 |
| 8 | FLUDARABINE PHOSPHATE | 15 | 0.0004 |
| 9 | MEROPENEM | 12 | 0.0004 |
| # | Drug class | Count |
|---|---|---|
| 0 | Corticosteroid [EPC] | 38 |
| 1 | Alkylating Drug [EPC] | 34 |
| 2 | Nucleoside Metabolic Inhibitor [EPC] | 24 |
| 3 | CD20-directed Cytolytic Antibody [EPC] | 18 |
| 4 | Folate Analog Metabolic Inhibitor [EPC] | 15 |
| 5 | Penem Antibacterial [EPC] | 12 |
| 6 | Azole Antifungal [EPC] | 8 |
| 7 | Lipid-based Polyene Antifungal [EPC] | 7 |
| 8 | Polyene Antifungal [EPC] | 7 |
| 9 | Glycopeptide Antibacterial [EPC] | 6 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Anthracycline Topoisomerase Inhibitor [EPC] | 2 | 0.0008 |
| 1 | Lipid-based Polyene Antifungal [EPC] | 7 | 0.0005 |
| 2 | Monobactam Antibacterial [EPC] | 1 | 0.0004 |
| 3 | Penem Antibacterial [EPC] | 12 | 0.0004 |
| 4 | Cytomegalovirus DNA Terminase Complex Inhibitor [EPC] | 1 | 0.0003 |
| 5 | CD33-directed Immunoconjugate [EPC] | 1 | 0.0003 |
| 6 | Bispecific CD20-directed CD3 T Cell Engager [EPC] | 1 | 0.0002 |
| 7 | Lipopeptide Antibacterial [EPC] | 2 | 0.0002 |
| 8 | CD19-directed Chimeric Antigen Receptor [EPC] | 2 | 0.0002 |
| 9 | Polyene Antifungal [EPC] | 7 | 0.0002 |